In this week’s video, Dr. Brian G.M. Durie explains how Next Generation Flow testing is sensitive enough to detect one myeloma cell in a one million cells.

Whereas MRD-testing is done in the bone marrow, NGF tests may be used to monitor plasma cells in the blood.

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at

Previous Post
Should a patient not have brain surgery for his Parkinson’s disease because he has myeloma skull lesions?
Next Post
Is it important for a multiple myeloma patient to see a myeloma specialist?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.